v3.25.0.1
Investments in and Advances to Joint Ventures - Summary of Financial Information for Unconsolidated Joint Ventures (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2024
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Schedule Of Equity Method Investments [Line Items]          
Current assets $ 2,462,400   $ 2,462,400 $ 2,137,526  
Total assets 5,487,962   5,487,962 4,804,061  
Current liabilities 1,915,644   1,915,644 1,410,884  
Total liabilities 2,953,473   2,953,473 2,427,346  
Total joint venture equity 2,416,389   2,416,389 2,287,211  
Investments in and advances to unconsolidated joint ventures 138,759   138,759 128,204  
Revenue 1,734,317 $ 1,535,676 6,750,576 5,442,749 $ 4,195,272
Costs     5,344,154 4,236,735 3,248,550
Net income attributable to Parsons Corporation 54,180 $ 39,750 235,053 161,149 96,664
Equity in (losses) earnings of unconsolidated joint ventures     (23,361) (47,751) 16,347
Unconsolidated Joint Ventures          
Schedule Of Equity Method Investments [Line Items]          
Current assets 1,477,950   1,477,950 1,607,953  
Noncurrent assets 431,476   431,476 483,693  
Total assets 1,909,426   1,909,426 2,091,646  
Current liabilities 947,072   947,072 1,057,113  
Noncurrent liabilities 469,808   469,808 518,647  
Total liabilities 1,416,880   1,416,880 1,575,760  
Total joint venture equity 492,546   492,546 515,886  
Investments in and advances to unconsolidated joint ventures $ 138,759   138,759 128,204  
Revenue     2,118,799 2,313,420 2,406,407
Costs     2,108,768 2,310,114 2,325,472
Net income attributable to Parsons Corporation     10,031 3,306 80,935
Unconsolidated Joint Ventures          
Schedule Of Equity Method Investments [Line Items]          
Equity in (losses) earnings of unconsolidated joint ventures     $ (23,361) $ (47,751) $ 16,347